Kite, A Gilead Company Presents New Data On Yescarta For Relapsed/Refractory Central Nervous System Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Kite, a Gilead Company, presented new data on Yescarta for relapsed/refractory central nervous system lymphoma at the 2024 ASCO Annual Meeting. The data shows no additional risks of adverse events and suggests efficacy with a median progression-free survival and durability of response of more than a year.
June 03, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences presented promising data on Yescarta for CNS lymphoma, showing no additional risks and suggesting efficacy with a median progression-free survival and durability of response of more than a year.
The positive data on Yescarta, showing no additional risks and suggesting efficacy, is likely to boost investor confidence in Gilead Sciences. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100